Press Releases
2024
First Patient Dosed in Endeavor BioMedicines’ Phase 2b WHISTLE-PF Trial Evaluating ENV-101 for the Treatment of Idiopathic Pulmonary Fibrosis
- ENV-101, a novel investigational Hedgehog signaling pathway inhibitor, has demonstrated clinical potential to improve lung function and total lung capacity, and reverse multiple key quantitative measures of lung fibrosis SAN DIEGO – November 20, 2024 – Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational...
Endeavor BioMedicines Appoints Bill Bradford, M.D., Ph.D., to Board of Directors
SAN DIEGO – September 12, 2024 – Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the appointment of Williamson “Bill” Bradford, M.D., Ph.D., to the company’s board of directors. Dr. Bradford brings over two...
New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines’ ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis
Data presented for the first time today during late-breaking oral session at the American Thoracic Society 2024 International Conference Patients who received ENV-101 experienced statistically significant improvements in lung function and total lung capacity, and reversal of multiple key quantitative measures of lung fibrosis through 12 weeks of treatment Findings reinforce potential...
Endeavor BioMedicines to Present New Data From Phase 2a Clinical Trial of ENV-101 at American Thoracic Society 2024 International Conference
Data from Phase 2a trial of novel Hedgehog (Hh) signaling pathway inhibitor in patients with idiopathic pulmonary fibrosis selected for featured late-breaking oral presentation on May 19 SAN DIEGO – May 1, 2024 – Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical...
Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines
– Proceeds will support clinical development of lead pipeline candidates: ENV-101 for fibrotic lung diseases including idiopathic pulmonary fibrosis, and ENV-501, a next-generation HER3-targeted antibody-drug conjugate, for solid tumors – – Oversubscribed crossover financing from large, top-tier life sciences investor syndicate led by AyurMaya, an affiliate of Matrix Capital Management – –...
Endeavor BioMedicines Announces Appointment of Chris Krueger, J.D., as Chief Operating Officer
SAN DIEGO – April 16, 2024 – Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the appointment of Chris Krueger, J.D., as Chief Operating Officer (COO). Mr. Krueger brings extensive experience from the...
Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D., as President and Vishaal Turakhia as Chief Financial Officer
SAN DIEGO – March 14, 2024 – Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the appointment of Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officer (CFO). Both Dr. Kariuki...
Endeavor BioMedicines Successfully Completes Phase 2a Trial of ENV-101 in Patients with Idiopathic Pulmonary Fibrosis
ENV-101 has potential to be the best-in-class treatment for idiopathic pulmonary fibrosis (IPF) Endeavor expects to initiate Phase 2b study of ENV-101 for the treatment of IPF and progressive fibrosing-interstitial lung disease (PF-ILD) in 2024 SAN DIEGO – January 24, 2024 – Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with...
2023
Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D., to Board of Directors
SAN DIEGO – December 19, 2023 – Endeavor BioMedicines, a clinical-stage company developing therapies for fibrotic disease and oncology, announced that the company has appointed Enoch Kariuki, Pharm.D. to the Endeavor BioMedicines Board of Directors. Dr. Kariuki is an established life sciences executive with extensive strategic, operational, and financial...
Endeavor BioMedicines Appoints Paul Frohna, M.D., Ph.D., as Chief Medical Officer
SAN DIEGO – November 2, 2023 – Endeavor BioMedicines, a clinical-stage company developing therapies for of fibrotic disease and oncology, today announced the appointment of Paul Frohna, M.D., Ph.D., as its Chief Medical Officer. Dr. Frohna is a physician-scientist with over 20 years of experience in the biotech industry...
Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)
Endeavor obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-HER3 ADC to be developed for patients with HER3-expressing tumors Hummingbird Bioscience to receive upfront and milestone payments up to $430 million, plus royalties, from Endeavor BioMedicines Hummingbird Bioscience to receive upfront and milestone payments up to $430 million, plus royalties, from Endeavor BioMedicines San...
2022
Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline
Three oncology and fibrotic disease programs in clinical development by end of 2022 SAN DIEGO – February 7, 2022 – Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, today announced the completion of a $101 million Series B financing, led by...
2021
Endeavor BioMedicines Doses First Patient in Phase 2 Clinical Trial of Taladegib (ENV-101) for Idiopathic Pulmonary Fibrosis; Appoints Chief Medical Officer
Dr. Srikanth Pendyala appointed Chief Medical Officer, bringing over 20 years of expertise in clinical research and translational sciences as company broadens its precision medicines pipeline Phase 2 clinical trial to assess safety and efficacy of taladegib, a Hedgehog pathway inhibitor, as a monotherapy in patients with IPF SAN DIEGO – September...
Endeavor BioMedicines Launches with $62 Million Series A Financing and Mission to Reverse the Course of Devastating Pulmonary Disease
Product candidate taladegib inhibits chronic Hedgehog signaling pathway, an underlying mechanism behind Idiopathic Pulmonary Fibrosis (IPF) Two Phase 2 clinical studies investigating taladegib’s potential to slow or reverse IPF disease progression expected to initiate in 2021 SAN DIEGO – January 7, 2021 – Endeavor BioMedicines, a biotechnology company developing new treatments...